Cranial Magnetic Resonance Imaging in the Staging of HER2-positive Breast Cancer Patients

Basit Öğe Kaydı
dc.contributor.authorKaplan, Muhammet A.
dc.contributor.authorInal, Ali
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorEkici, Faysal
dc.contributor.authorFirat, Ugur
dc.contributor.authorZincircioglu, Seyit B.
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: The aim of the current study was to evaluate whether early detection of brain metastases (BMs) could improve survival outcomes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients. Material and Methods: HER2-positive breast cancer patients without BMs who had no neurological symptoms within 12 months from diagnosis or relapse time of the disease were included in the study. The patients were distributed into 2 groups: Group 1 comprised patients without metastases; group 2 comprised patients with metastases. The symptomatic historic control group with BMs was defined retrospectively for survival comparisons. Results: 55 (57.3%) and 41(42.7%) patients were in groups 1 and 2, respectively. 11 of the 96 patients (11.5%) had occult BMs, and 9 of them were in group 2 whereas only 2 patients were in group 1 (22% vs. 3.6%, respectively; p = 0.008). While the median survival times from the first metastasis (28.7 vs. 22.5 months, respectively; p = 0.561) and BM (6.8 vs. 6.1 months, respectively; p = 0.511) were similar, cerebral death was numerically different (16.7% vs. 46.3%; p = 0.221) between asymptomatic (n = 9) and symptomatic patients (n = 53). Conclusions: BMs were detected very rarely in asymptomatic, non-metastatic HER2-positive breast cancer patients compared with asymptomatic, metastatic patients. Furthermore, although early detection of BMs decreases the cerebral death rate, it does not prolong the survival rate in metastatic patients.en_US
dc.identifier.doi10.1159/000349950
dc.identifier.endpage181en_US
dc.identifier.issn0378-584X
dc.identifier.issn1423-0240
dc.identifier.issue4en_US
dc.identifier.pmid23548965
dc.identifier.scopus2-s2.0-84876168016
dc.identifier.scopusqualityQ4
dc.identifier.startpage176en_US
dc.identifier.urihttps://doi.org/10.1159/000349950
dc.identifier.urihttps://hdl.handle.net/11468/17975
dc.identifier.volume36en_US
dc.identifier.wosWOS:000317536100003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHer2 Overexpressionen_US
dc.subjectBreast Canceren_US
dc.subjectAsymptomatic Brain Metastasesen_US
dc.titleCranial Magnetic Resonance Imaging in the Staging of HER2-positive Breast Cancer Patientsen_US
dc.titleCranial Magnetic Resonance Imaging in the Staging of HER2-positive Breast Cancer Patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu